Schistosomiasis in Formal and Non-Formal Schools in Uganda: Implications for Control Programmes

Learn more about:
Related Clinical Trial
Correlating Protection Against Malaria With Serum Profiles Against Plasmodium Falciparum Antigen Repertoires Prevalence of Chronic Kidney Disease (CKD) and Risk Factors in Sub-Saharan Africa S. Japonicum and Pregnancy Outcomes Artemisinin-based Combination Therapy-Intermittent Preventive Treatment (ACT-IPT) Trial Among Schoolchildren in Kassena-Nankana, Ghana Study of Safety and Immune Response of the Sm14 Vaccine in Adults of Endemic Regions L-praziquantel Orodispersible Tablets (L-PZQ ODT) in Schistosoma Infected Children The Effect of Praziquantel Treatment on Schistosoma Mansoni Morbidity and re-Infection Along Lake Victoria, Uganda Praziquantel in Children Under Age 4 Schistosoma Haematobium Infections and Praziquantel Antioxidant Supplements in the Reversal of Schistosomal Peri-portal Fibrosis Single-sex Controlled Human Schistosomiasis Infection: Safety and Dose Finding A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel)(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults Single-sex Female Controlled Human Schistosomiasis Mansoni Infection An Open Label Dose Finding Safety and Efficacy in Children and Infants Infected With Schistosomiasis (S.Mansoni) Schistosomiasis Effect on Response to Vaccines, Anaemia and Nutritional Status of Children of Northern Senegal Praziquantel-Pharmacokinetic Study Schistosomiasis in Women of Reproductive Age in Burkina Faso: Implications for Control Iron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia Schistosomiasis in Formal and Non-Formal Schools in Uganda: Implications for Control Programmes Using Community-Based Volunteers to Reach Non-Enrolled School Aged Children Through Community-Directed Treatment of Schistosomiasis in School-Aged Children in Rural Northern Ghana Sm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults Clinical Trial of Bilhvax,a Vaccine Candidate Against Schistosomiasis A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults Treatment of Female Genital Schistosomiasis (FGS) With Praziquantel: A Proof-of-Concept Study Schistosomiasis in Senegal Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST) Childhood Schistosomiasis: a Novel Strategy Extending the Benefits/Reach of Antihelminthic Treatment Anti-Schistosomiasis Vaccine: Sm14 Phase 2b-Sn in School Children Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis Arachidonic Acid Treatment Against Schistosomiasis Infection in Children Detection of Schistosomiasis CAA in Travellers After High-risk Water Contact Evaluation of Strategies for Improved Uptake of Preventive Treatment for Intestinal Schistosomiasis Health Benefits of Repeated Treatment in Pediatric Schistosomiasis Seropositivity and Adverse Birth Events in Migrants From Bilharzia-endemic Areas Women and Children as the Focus for Control of Schistosomiasis Infections in the Irrigations Area of Burkina Faso

Brief Title

Schistosomiasis in Formal and Non-Formal Schools in Uganda: Implications for Control Programmes

Official Title

Schistosomiasis in Formal and Non-Formal Schools in Uganda: Implications for Control

Brief Summary

      Current efforts to control schistosomiasis and soil-transmitted helminthes infections focus
      on the school-age population, and school-based treatment delivery programs offer a major cost
      advantages because of the use of the existing school infrastructure and the fact that
      schoolchildren are accessible through schools. However, in many developing countries, large
      numbers of school-age children are not in school and this has raised questions about the
      effectiveness of school-based programs in reaching non-enrolled children. Increasingly, the
      non-formal education sector is providing a growing solution to the problem of poor enrolment
      in basic education, especially in sub-Saharan Africa, and has recently been used to deliver
      praziquantel as part of a national schistosomiasis control program in Uganda. However, it is
      unclear how effective this program has been in reaching children who attend non-formal
      schools and whether the program has been reaching children from the poorest households.
    

Detailed Description

      This study will compare infection and nutritional status of children enrolled in formal
      schools and non-formal schools, and non-enrolled children in Nakasongola District in Uganda,
      and investigate the process and impact of treatment delivered by the national control
      program. The study will consist of household surveys and cross-sectional parasitological and
      hematological surveys, with follow-up six months later. The evaluation will take place over
      the course of a year and will:

        -  Compare the infection and nutritional status of children enrolled in formal schools and
           non-formal schools, and non-enrolled children in Nakasongola District, Uganda

        -  Compare programmatic process indicators, including enrolment rates, attendance rates,
           access to water and sanitation, treatment coverage in formal and non-formal schools

        -  Investigate the impact of treatment on intensity of infection and reinfection rates in
           formal and non-formal schools.
    


Study Type

Observational




Condition

Schistosomiasis


Study Arms / Comparison Groups

 2
Description:  children enrolled in formal schools and children not enrolled in formal schools

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information



Estimated Enrollment

1293

Start Date

December 2006

Completion Date

June 2007


Eligibility Criteria

        Inclusion Criteria:

          -  School children in grad 1 and 2
      

Gender

All

Ages

6 Years - 18 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

Narcis Kabatereine, Dr, , 

Location Countries

Uganda

Location Countries

Uganda

Administrative Informations


NCT ID

NCT00463593

Organization ID

SRP-UG-NK-06



Study Sponsor

DBL -Institute for Health Research and Development


Study Sponsor

Narcis Kabatereine, Dr, Principal Investigator, Vector Control Division, Ministry of Health Uganda


Verification Date

January 2008